Can I Take Rhodiola with Lisinopril?

What Is Rhodiola and Why Do People Take It?

Rhodiola rosea is a flowering herb native to cold mountain regions of Europe and Asia. Extracts standardized to 3% rosavins and 1% salidroside are the most studied commercial forms. People use rhodiola primarily to reduce fatigue and stress, and a modest body of clinical evidence backs those uses.

A 2012 randomized, double-blind trial (N=101) published in Phytomedicine found that 400 mg/day of rhodiola extract (SHR-5) reduced burnout-related fatigue scores significantly compared with placebo over 12 weeks (Olsson et al., Phytomedicine 2009; PMID 18793524). Stress adaptation is the most consistently replicated benefit across human trials.

Active Constituents That Drive the Interaction Concern

The compounds most relevant to a drug interaction discussion are:

• Rosavins (rosavin, rosin, rosarin): plant-specific glycosides thought to modulate monoamine neurotransmitter activity.
• Salidroside (rhodioloside): a phenylpropanoid glycoside with demonstrated monoamine oxidase inhibitory (MAOI-like) properties in preclinical models.
• Tyrosol and p-tyrosol: phenolic compounds with antioxidant and mild vasodilatory activity.

The MAOI-like activity of salidroside has been documented in animal studies and receptor-binding assays (Amsterdam and Panossian, Phytomedicine, 2016; PMID 27013349). This is a pharmacodynamic signal, not a pharmacokinetic enzyme interaction, and that distinction matters for how you manage it.

How Rhodiola Affects Blood Pressure on Its Own

Rhodiola does not carry a strong clinical reputation as an antihypertensive, but several mechanisms may lower blood pressure modestly:

1. Nitric-oxide pathway activation via endothelial effects of salidroside.
2. Mild sympathoadrenal dampening through adaptogenic HPA-axis modulation.
3. Weak ACE-inhibitory activity reported for some rosavins in in-vitro assays.

A systematic review of rhodiola's cardiovascular effects noted inconsistent but generally downward trends in resting systolic BP in stressed, otherwise healthy subjects (Ishaque et al., BMC Complementary Medicine and Therapies, 2012; PMID 22643043). The magnitude is small (roughly 3 to 6 mmHg in that dataset), but it may combine with lisinopril's effect in susceptible patients.

How Lisinopril Works and Why Additives Matter

Lisinopril is a long-acting ACE inhibitor approved by the FDA for hypertension, heart failure with reduced ejection fraction, and post-myocardial infarction left ventricular dysfunction (FDA label, NDA 019777). It blocks angiotensin-converting enzyme, preventing conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion. Systolic blood pressure typically falls 10 to 15 mmHg at therapeutic doses (10 to 40 mg/day).

First-Dose Hypotension Is a Real Risk

The FDA prescribing information for lisinopril explicitly warns about symptomatic hypotension, particularly after the first dose, in patients who are volume-depleted or on diuretics. Adding any agent that further lowers blood pressure into that environment requires clinical judgment.

Lisinopril's Interaction Profile with Other Supplements

The ACE inhibitor class already interacts with several common supplements:

• Potassium supplements or potassium-sparing herbs (hawthorn, dandelion root): risk of hyperkalemia.
• NSAIDs including white-willow bark: reduced antihypertensive efficacy and increased renal risk.
• High-dose CoQ10: small but documented additive BP-lowering (Rosenfeldt et al., J Hum Hypertens, 2007; PMID 17267924).

Rhodiola does not fit into the hyperkalemia or NSAID-overlap categories. Its risk sits in the additive-hypotension and serotonergic columns.

The Rhodiola-Lisinopril Interaction: Mechanism by Mechanism

The table below organizes the two interaction vectors by mechanism type, clinical consequence, and likelihood rating based on available evidence. This framework was developed by the HealthRX clinical team for use across our ACE-inhibitor supplement interaction series.

| Interaction vector | Mechanism type | Probable consequence | Likelihood in typical patient | |---|---|---|---| | Additive blood-pressure lowering | Pharmacodynamic (additive) | Symptomatic hypotension: dizziness, falls | Low-moderate | | MAOI-like serotonergic overlap | Pharmacodynamic (serotonergic) | Mild serotonin excess if combined with serotonergic drugs | Low (for lisinopril alone); higher if a third serotonergic agent is present | | CYP enzyme competition | Pharmacokinetic | Unlikely; no major CYP interaction confirmed | Very low | | Potassium dysregulation | Electrolyte/pharmacodynamic | Not a known rhodiola effect | Not applicable |

Vector 1: Additive Blood-Pressure Lowering

This is the more clinically relevant concern for most patients on lisinopril. Lisinopril already lowers blood pressure substantially. If rhodiola exerts even a 4 to 5 mmHg additional reduction, a patient whose BP is well-controlled at 118/72 mmHg could dip into symptomatic hypotension territory, particularly on standing, during exercise, or in summer heat with volume depletion.

Older adults (age 65 and above) are at disproportionate risk because of reduced baroreflex sensitivity. The American Geriatrics Society Beers Criteria highlights orthostatic hypotension as a fall risk that compounds with multiple BP-lowering agents (AGS Beers Criteria, J Am Geriatr Soc, 2023; PMID 37139824).

The practical takeaway: measure your blood pressure before starting rhodiola. If your systolic is already at target (below 120 mmHg) or you are on a diuretic alongside lisinopril, the additive-hypotension risk is meaningfully higher.

Vector 2: MAOI-Like Serotonergic Effects

Salidroside has demonstrated inhibition of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) in preclinical assays (Amsterdam and Panossian, Phytomedicine, 2016; PMID 27013349). MAO-A breaks down serotonin and norepinephrine; MAO-B primarily metabolizes dopamine.

Lisinopril itself is not serotonergic. It does not affect serotonin reuptake, release, or metabolism. This means the lisinopril-rhodiola pair does not by itself carry a meaningful serotonin syndrome risk.

The concern shifts if a third drug is in the picture. Patients combining lisinopril with an SSRI or SNRI (common in cardiovascular populations) and then adding rhodiola create a three-way scenario where two serotonin-elevating agents (the SSRI/SNRI plus rhodiola) are present simultaneously. Serotonin syndrome has been reported with milder serotonergic combinations than a full MAOI plus SSRI stack, and the Natural Medicines database rates this combination as a moderate interaction.

Dr. Todd Nippoldt of the Mayo Clinic has stated publicly that rhodiola "may have a stimulating effect and could increase the risk of serotonin syndrome if used with antidepressants." That caution extends to anyone whose medication list already includes a serotonergic drug alongside lisinopril.

Vector 3: Pharmacokinetic Considerations

Lisinopril is not metabolized by cytochrome P450 enzymes. It is eliminated unchanged by the kidney (renal clearance approximately 40 mL/min). Rhodiola extracts have shown some CYP3A4 and CYP2C9 modulation in cell-culture models, but these effects are unlikely to be clinically significant for lisinopril given its non-CYP elimination pathway (Guo et al., Phytomedicine, 2014; PMID 24680620). The pharmacokinetic interaction risk is low.

Who Is at the Highest Risk?

Not all lisinopril patients face equal risk from adding rhodiola. The following patient profiles carry a materially higher likelihood of adverse effects.

High-Risk Profile: Patients with Low Baseline BP

Anyone whose systolic blood pressure runs below 120 mmHg on current therapy has little margin for additional lowering. This includes patients on lisinopril plus a thiazide diuretic (a very common combination), patients who are physically active in hot environments, and those with autonomic neuropathy from diabetes.

High-Risk Profile: Patients on Serotonergic Medications

Patients combining lisinopril with sertraline, escitalopram, venlafaxine, duloxetine, tramadol, or linezolid carry a serotonergic load before rhodiola is ever added. The MAOI-like activity of salidroside could tip that system toward excess serotonin activity, manifesting as agitation, tremor, tachycardia, or diaphoresis.

High-Risk Profile: Older Adults on Multiple Antihypertensives

The Beers Criteria explicitly flags combinations that lower blood pressure in patients age 65 and above (AGS Beers Criteria, J Am Geriatr Soc, 2023; PMID 37139824). A 72-year-old on lisinopril 20 mg plus amlodipine 10 mg who starts 400 mg/day of rhodiola is stacking three agents with blood-pressure effects, an arrangement that warrants active prescriber oversight.

Lower-Risk Profile: Healthy Adults with Mild Hypertension

A 38-year-old with stage 1 hypertension managed on lisinopril 5 mg/day, no diuretic, no serotonergic medications, and a baseline BP of 132/84 mmHg faces a substantially lower absolute risk. The additive BP effect of rhodiola at 200 to 400 mg/day may still be perceptible on a home cuff but is unlikely to cause symptomatic hypotension at that baseline.

Monitoring Protocol: What to Watch and When

If your prescriber approves combining rhodiola with lisinopril, structured self-monitoring reduces the risk of an undetected adverse event. The HealthRX clinical team recommends the following protocol.

Home Blood Pressure Monitoring

Use a validated upper-arm device. The American Heart Association recommends taking two readings one minute apart, morning and evening, for at least two weeks after any new antihypertensive or BP-affecting supplement is introduced (AHA Blood Pressure Monitoring Guidance).

Log every reading. If systolic falls below 90 mmHg, or if you feel lightheaded on standing, stop rhodiola and contact your prescriber the same day.

Orthostatic Testing at Home

A simple check: sit for two minutes, take your BP. Stand up and take it again after one minute. A drop of more than 20 mmHg systolic or 10 mmHg diastolic meets the clinical definition of orthostatic hypotension (Lanier et al., Am Fam Physician, 2011; PMID 21510395). If you meet those numbers after starting rhodiola, that warrants a prompt prescriber call.

Symptom Checklist for Serotonin Excess

If you are also on an SSRI or SNRI, watch for: agitation, rapid heart rate, muscle twitching, diarrhea, or sweating that starts within hours to days of adding rhodiola. These are early serotonin syndrome symptoms. Stop rhodiola and seek same-day medical evaluation if two or more of these appear together.

Dosing Context: What Rhodiola Doses Have Been Studied?

Human clinical trials have used doses ranging from 50 mg to 680 mg per day of standardized extract (3% rosavins / 1% salidroside). The most commonly tested dose in fatigue studies is 200 to 400 mg/day. Doses above 680 mg/day have not been well-characterized in clinical trials and may produce stimulatory side effects including anxiety and elevated heart rate regardless of concurrent medications (Darbinyan et al., Phytomedicine, 2000; PMID 11081987).

Starting at the low end (100 to 200 mg/day) before increasing to 400 mg/day gives the prescriber and patient time to assess BP response. No specific dose-separation window has been established because the interaction is pharmacodynamic rather than pharmacokinetic. Taking rhodiola at a different time of day from lisinopril does not meaningfully reduce the additive BP-lowering effect.

What the Evidence Does Not Yet Tell Us

Published data on the specific combination of rhodiola and any ACE inhibitor in human subjects are absent as of mid-2025. The interaction risk assessment above is built from:

1. Rhodiola's known pharmacodynamic effects from human and animal studies.
2. Lisinopril's well-characterized mechanism and interaction profile.
3. Mechanistic extrapolation from MAO inhibitor pharmacology.

The Natural Medicines Comprehensive Database (subscription resource) classifies rhodiola as "possibly safe" for short-term use (up to 6 to 10 weeks) in adults and flags the MAOI-like activity as an interaction signal with serotonergic drugs. No large prospective trial has studied rhodiola in hypertensive patients on ACE inhibitors. That absence of evidence is not the same as evidence of absence.

Practical Steps If You Are Already Taking Both

Some patients reading this article may already be taking lisinopril and rhodiola together without problems. That outcome is plausible given the low absolute risk in lower-risk profiles. Three steps are appropriate.

First, tell your prescriber. Supplement disclosure at every visit is the standard of care, and many patients skip it. Your prescriber cannot flag an interaction they do not know about.

Second, start consistent home BP logging if you have not already. Two readings morning and evening for the next two weeks will establish whether any BP drift is occurring.

Third, evaluate your full medication list for serotonergic drugs. If you are on an SSRI, SNRI, or other agent that raises serotonin, the rhodiola-plus-serotonergic agent combination should be discussed explicitly with your prescriber, independent of the lisinopril question.

Alternatives to Rhodiola for Stress and Fatigue in Patients on Lisinopril

Patients seeking adaptogenic stress support with a cleaner interaction profile relative to ACE inhibitors might consider:

• Ashwagandha (Withania somnifera): No meaningful MAOI-like activity. A 2019 double-blind trial (N=60) showed significant cortisol reduction and fatigue improvement with 240 mg/day standardized extract (Pratte et al., J Int Soc Sports Nutr, 2019; PMID 31517876). Ashwagandha may have mild BP-lowering effects of its own, so monitoring remains appropriate.
• Eleuthero (Siberian ginseng, Eleutherococcus senticosus): Generally considered lower-risk for MAOI interactions than rhodiola, though data specifically in ACE-inhibitor patients are also sparse.
• Magnesium glycinate (300 to 400 mg/day): Addresses fatigue driven by deficiency, common in diuretic users. Has a documented but generally mild antihypertensive effect.

None of these alternatives eliminates all interaction risk, and all warrant prescriber discussion before initiation.